Merck Cuts U.S. Sales Force By 1,200
This article was originally published in The Pink Sheet Daily
Executive Summary
Combined with earlier cutbacks, Merck has eliminated 1,600 positions, or 20 percent, of its force since 2005, firm tells the DAILY.
You may also be interested in...
Merck: Second “Not Approvable” Letter In Two Days – This Time, Cordaptive
FDA nixes name, too, for anti-cholesterol niacin/laropiprant combo.
Wyeth Kicks Off “Project Impact” As Protonix Generics Threaten Bottom Line
Drug revenues jump 10 percent for the fourth quarter and full year, and dual-fronted patent fight goes on.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.